TLX - Earnings announcements

Webcast and conference call to be held today, Tuesday March 10 at 9:30 a.m. AEDT (Monday March 9 at 6:30 p.m. EDT). Investors can register at the following link: https://s1.c-conf.com/diamondpass/10053620-ju7y6t.html MELBOURNE, Australia and INDIANAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces that Part 1 of the ProstACT Global Phase 3 study, the safety and dosimetry lead-in for its therapeutic candidate – TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) – has achieved its primary objectives, demonstrating an acceptable safety and tolerability profile with no new safety signals observed. Key findings includ

MELBOURNE, Australia and INDIANAPOLIS, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, ", Telix", ) today announces its financial results for the year ended December 31, 2025. FY 2025 key results1 Group performance2: Double-digit revenue growth and positive adjusted operating cash flow Revenue of US$803.8 million, up by 56%3 and achieving upsized full year guidance4.US$157.1 million invested in research and development (R&D) product development for late-stage therapeutics and precision medicine pipeline assets5, in line with stated FY 2025 guidance.Adjusted EBITDA6 of US$39.5 million, reflective of increased operating expenditure driven by strategi

MELBOURNE, Australia and INDIANAPOLIS, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") advises that it will release its full year results for the period ended 31 December 2025 on Friday, 20 February 2026 AEDT (Thursday, 19 February 2026 EST). An investor webcast and conference call will be held at 9:30 a.m. AEDT, Friday, 20 February 2026 (5:30 p.m. EST, Thursday, 19 February 2026).  Participants can register at the following link: https://edge.media-server.com/mmc/p/famdpwzh About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceu

NEW YORK, Nov. 30, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP reminds purchasers or acquirers of Telix Pharmaceuticals Ltd. (NASDAQ:TLX) ("Telix") American Depositary Shares ("ADS") between February 21, 2025 and August 28, 2025 (the "Class Period") have until January 9, 2026 to seek appointment as lead plaintiff. PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION Allegations: The lawsuit alleges violations of the Securities Exchange Act of 1934, claiming that Telix and its executives: Overstated progress on the company's prostate cancer therapeutic candidates.Overstated the quality of its supply chain and partner operations. Key Events: On Febr

MELBOURNE, Australia and INDIANAPOLIS, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, ", Telix", ) today announces its financial results for the half-year ended 30 June 2025. All figures are in USD unless stated otherwise. H1 2025 key results1 Group performance2: Reflects strategic investment for long-term value creation Revenue of $390.4 million, up by 63%3 and on track to meet full year guidance4.Group gross profit margin of 53% reflects product mix change to include third-party RLS sales. Illuccix® margin remains stable.Adjusted EBITDA5 of $21.1 million, reflective of increased operating expenditure driven by strategic acquisitions, inves

MELBOURNE, Australia and INDIANAPOLIS, July 30, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today advises that it will release its financial results for the half-year ended 30 June 2025 on Thursday 21 August 2025. An investor webcast and conference call will be held at 9.30am AEST on Thursday 21 August 2025 (7.30pm EDT Wednesday 20 August 2025).    Participants can register for the webcast at the following link: https://edge.media-server.com/mmc/p/x4gytx8w/ Participants can register for the teleconference here: https://s1.c-conf.com/diamondpass/10049152-x745re.html About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focu